Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Net Cash Flow (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Net Cash Flow data on record, last reported at $9.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 61.28% year-over-year to $9.0 million; the TTM value through Dec 2025 reached -$16.2 million, up 30.3%, while the annual FY2025 figure was -$16.2 million, 30.3% up from the prior year.
  • Net Cash Flow reached $9.0 million in Q4 2025 per VRCA's latest filing, up from $5.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $34.7 million in Q1 2022 and bottomed at -$20.6 million in Q1 2024.
  • Average Net Cash Flow over 5 years is $973050.0, with a median of -$4.8 million recorded in 2021.
  • The widest YoY moves for Net Cash Flow: up 325.11% in 2023, down 920.06% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$4.7 million in 2021, then soared by 138.38% to $1.8 million in 2022, then plummeted by 920.06% to -$14.8 million in 2023, then skyrocketed by 258.32% to $23.4 million in 2024, then tumbled by 61.28% to $9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $9.0 million in Q4 2025, $5.7 million in Q3 2025, and -$14.2 million in Q2 2025.